文献速递淋巴瘤

高级别B细胞淋巴瘤非特指型:一项LLMPP研究

High-grade B-cell lymphoma, not otherwise specified: an LLMPP study.
PubMed 文献 · Blood Adv · 2025-01-01

该研究对92例高级别B细胞淋巴瘤非特指型(HGBCL-NOS)肿瘤进行分子特征分析,并与弥漫性大B细胞淋巴瘤非特指型(DLBCL-NOS)和伯基特淋巴瘤(BL)比较。结果显示HGBCL-NOS分子景观异质,富集BL特征,如MYC重排47% vs 6%、暗区特征表达45% vs 7%。集中病理复审将近半数肿瘤重新分类为DLBCL-NOS,但未识别出更同质的HGBCL-NOS群体。

要点

  • HGBCL-NOS中MYC重排频率为47%,显著高于DLBCL-NOS的6%。
  • 暗区特征(DZsig)在HGBCL-NOS中表达率为45%,而DLBCL-NOS为7%。
  • 集中病理复审将近半数HGBCL-NOS重新分类为DLBCL-NOS,但确认与重新分类肿瘤间特征无差异。

核心结论

  • 分子检测可使一部分HGBCL-NOS归入已确立的类别。
  • 基于其罕见性和诊断挑战,作者认为应考虑在生物标志物驱动的DLBCL试验中更广泛地纳入HGBCL-NOS。

研究设计与样本

  • 研究分析了来自淋巴瘤/白血病分子分析项目(LLMPP)多个中心的92例HGBCL-NOS肿瘤。
  • 利用DLBCL-NOS和BL的对比队列及这些实体中描述的分子框架进行分析。
  • 进行了集中病理复审。

主要发现

  • 细胞起源分型显示59%为生发中心B细胞样(GCB),25%为活化B细胞样(ABC)。
  • LymphGen遗传分类器为34%的HGBCL-NOS分配了遗传亚型,低于DLBCL-NOS的66%。
  • HGBCL-NOS与DLBCL-NOS的鉴别特征包括MYC重排(47% vs 6%)、暗区特征(DZsig)表达(45% vs 7%)以及ID3、MYC、CCND3和TP53突变更频繁。
  • 一种区分DLBCL-NOS与BL的遗传分类器将53%的DZsig+肿瘤分类为BL样,被分类为DLBCL样的肿瘤常伴有BCL2重排。
  • 在DZsig- GCB肿瘤中,95%为DLBCL样。

关键数值与推荐

  • LymphGen将31%的ABC亚型分类为MCD。
  • 集中病理复审将几乎一半肿瘤重新分类为DLBCL-NOS,但未发现确认与重新分类肿瘤之间特征有差异。

临床怎么用

  • 作者认为,基于HGBCL-NOS的罕见性和诊断挑战,应考虑在生物标志物驱动的DLBCL试验中更广泛地纳入HGBCL-NOS。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Molecular characterization of high-grade B-cell lymphoma, not otherwise specified (HGBCL-NOS), is hindered by its rarity, evolving definition, and poor diagnostic reproducibility. To address this challenge, we analyzed 92 HGBCL-NOS tumors collected across Lymphoma/Leukemia Molecular Profiling Project sites. Leveraging comparison cohorts of diffuse large B-cell lymphoma, NOS (DLBCL-NOS) and Burkitt lymphoma (BL), and molecular frameworks described in these entities, our analysis revealed a heterogenous molecular landscape, reminiscent of DLBCL-NOS but with an enrichment of BL features. By cell-of-origin classification, 59% were germinal center B-cell-like (GCB), and 25% were activated B-cell-like (ABC). LymphGen, a genetic classifier for DLBCL-NOS, assigned a genetic subtype to 34% of HGBCL-NOS. Although classification rate was lower than in DLBCL-NOS (66%), assigned subtypes spanned the spectrum of LymphGen classes, including 31% of ABCs classified as MCD. Features differentiating HGBCL-NOS from DLBCL-NOS included MYC rearrangement (47% vs 6%); dark zone signature (DZsig) expression (45% vs 7%); and more frequent mutation of ID3, MYC, CCND3, and TP53, all common to BL. A genetic classifier that differentiates DLBCL-NOS from BL classified 53% of DZsig+ tumors as BL-like, and those classified as DLBCL-like were frequently BCL2-rearranged. Among DZsig- GCB tumors, 95% were DLBCL-like. Centralized pathology review reclassified almost half of tumors as DLBCL-NOS but did not identify a more homogenous HGBCL-NOS population, with no difference in features between confirmed and reclassified tumors. In conclusion, molecular testing enables a subset of HGBCL-NOS to be assigned to established categories. Based on rarity and diagnostic challenges, broader inclusion of HGBCL-NOS should be considered in biomarker-driven DLBCL trials.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Collinge B, Hilton LK, Wong J, et al. High-grade B-cell lymphoma, not otherwise specified: an LLMPP study. Blood Adv. 2025. PMID: 40674706. doi:10.1182/bloodadvances.2025016651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。